PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
31.77%
Cash & equivalents growing 31.77% while CRVO's declined -15.49%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
31.77%
Below half of CRVO's -15.49%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.02%
Below half of CRVO's -17.20%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.80%
Below half CRVO's -14.46%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.28%
Below half of CRVO's -3.10%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Below half of CRVO's -13.12%. Michael Burry sees a potential red flag for stagnation or capital shortage.
2.77%
Less than half of CRVO's -61.33%. David Dodd sees a more disciplined AP approach or lower volume.
1023.68%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.85%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
1.86%
Less than half of CRVO's -9.35%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.95%
Above 1.5x CRVO's -5.15%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of CRVO's -8.68%. David Dodd sees far fewer liability expansions relative to competitor.
28.57%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-2.84%
0.5-0.75x CRVO's -3.99%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
34.98%
Below half CRVO's -13.61%. Michael Burry sees potential underperformance in building shareholder capital.
31.41%
Below half CRVO's -13.12%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-15.85%
Similar yoy changes to CRVO's -14.60%. Walter Schloss notes parallel total debt strategies.
-32.66%
Less than half of CRVO's 15.50%. David Dodd sees better deleveraging or stronger cash buildup than competitor.